PART I . Our Business Overview Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatins strategy is to develop products and then form marketing collaborations with industry leaders to maximize product commercial potential. T...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-23 | 2025-06-30 | 0001654954-25-011030 | EDGAR | 70K words |
| 2024-09-30 | 2024-06-30 | 0001654954-24-012498 | EDGAR | — |
| 2023-09-28 | 2023-06-30 | 0001654954-23-012335 | EDGAR | — |
| 2022-09-22 | 2022-06-30 | 0001654954-22-012862 | EDGAR | — |
| 2021-09-28 | 2021-06-30 | 0001654954-21-010495 | EDGAR | — |
| 2020-09-25 | 2020-06-30 | 0001654954-20-010471 | EDGAR | — |
| 2019-09-12 | 2019-06-30 | 0001654954-19-010679 | EDGAR | — |
| 2018-09-13 | 2018-06-30 | 0001654954-18-010150 | EDGAR | — |
| 2017-09-25 | 2017-06-30 | 0001654954-17-008792 | EDGAR | — |
| 2016-09-19 | 2016-06-30 | 0001654954-16-002272 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001493152-26-006969 | EDGAR | 21K words |
| 2025-11-14 | 2025-09-30 | 0001654954-25-013091 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001654954-25-005610 | EDGAR | — |
| 2025-02-13 | 2024-12-31 | 0001654954-25-001431 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001654954-24-014335 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001654954-24-006292 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0001654954-24-001789 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001654954-23-014251 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001654954-23-006575 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0001654954-23-001726 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001654954-22-015282 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001654954-22-006963 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-11-12 | 0001654954-25-012928 | EDGAR | 1K words |
| 2025-11-06 | 0001654954-25-012641 | EDGAR | — |
| 2025-09-22 | 0001654954-25-010973 | EDGAR | — |
| 2025-09-10 | 0001654954-25-010576 | EDGAR | — |
| 2025-08-18 | 0001654954-25-009743 | EDGAR | — |
| 2025-08-08 | 0001654954-25-009290 | EDGAR | — |
| 2025-07-29 | 0001654954-25-008579 | EDGAR | — |
| 2025-07-09 | 0001654954-25-007872 | EDGAR | — |
| 2025-06-13 | 0001654954-25-006936 | EDGAR | — |
| 2025-05-08 | 0001654954-25-005296 | EDGAR | — |
393 total filings indexed. 361 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000911216 |
| Ticker | PTNT |
| Exchange | — |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NJ |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report